Gilead Sciences Inc. has named former Genentech Inc. executive Merdad Parsey as the next chief medical officer, effective Nov. 1.
Parsey will oversee Gilead's global clinical development and medical affairs organizations.
Previously, Parsey was senior vice president for early clinical development for Genentech's research and early development group. Genentech is a unit of Roche Holding AG. Parsey has also held roles at Regeneron Pharmaceuticals Inc. and Merck & Co. Inc.
